Skip to main navigation

Immunocore

Primary Menu

Overview
News & Events
Stock Information
- Stock Quote & Chart
- Analysts Coverage
Corporate Governance
Financials & Filings
- SEC Filings
IR Resources

Primary Menu

Overview
News & Events
Stock Information
- Stock Quote & Chart
- Analysts Coverage
Corporate Governance
Financials & Filings
- SEC Filings
IR Resources

News Releases

Breadcrumb

Home /
Investor Relations /
News & Events /
News Releases

Year

4 June 2021

Immunocore presents clinical data further characterizing the overall survival benefit of tebentafusp in metastatic uveal melanoma at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting

27 May 2021

Immunocore to present at upcoming investor conferences

18 May 2021

Immunocore announces dosing of first patient with ImmTAV® bispecific molecule for chronic Hepatitis B

12 May 2021

Immunocore Reports First Quarter 2021 Financial Results

28 April 2021

Immunocore Announces Upcoming Presentations at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting

12 April 2021

Immunocore presents phase 3 data comparing tebentafusp with investigator’s choice in the clinical trial plenary session at the American Association for Cancer Research 2021 Annual Meeting

25 March 2021

Immunocore Provides Business Update and Reports Full Year 2020 Financial Results

10 March 2021

Immunocore Announces Upcoming Presentations at the American Association for Cancer Research (AACR) 2021 Annual Meeting

19 February 2021

Immunocore’s tebentafusp granted Breakthrough Therapy Designation for unresectable or metastatic uveal melanoma from FDA

16 February 2021

Immunocore announces key appointments to management and Board

Pagination

Current page 1
Page 2
Page 3
Page 4
Page 5
Page 6
Page 7
Page 8
Page 9
…
Next page
Last page

Displaying 1 - 10 of 115

Site - Shareholder Tools

Immunocore

Site - Footer Social

About us
Our science
Our therapy areas
For patients

News
Careers
Contact us

Privacy and Social Media Guidelines
Cookies
Payments and Disclosures
Clinical trials

©2021 Immunocore, Ltd. All rights reserved. ImmTAC, ImmTAV, ImmTAB, ImmTAAI and ImmTAX are all registered trademarks of Immunocore, Ltd